These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 31279564

  • 1. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.
    Klein NP, Block SL, Essink B, Barbi S, Smolenov I, Keshavan P.
    Vaccine; 2019 Jul 26; 37(32):4460-4467. PubMed ID: 31279564
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM.
    Pediatr Infect Dis J; 2015 Dec 26; 34(12):e298-307. PubMed ID: 26780033
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J, Drazan D, Czajka H, Maguire J, Pregaldien JL, Seppa I, Maansson R, O'Neill R, Balmer P, Jodar L, Jansen KU, Anderson AS, Perez JL, Beeslaar J.
    Lancet Infect Dis; 2023 Dec 26; 23(12):1370-1382. PubMed ID: 37579773
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP, Habanec T, Kosina P, Shah NR, Kolhe D, Miller JM, Hezareh M, Van der Wielen M.
    Vaccine; 2018 Apr 19; 36(17):2356-2363. PubMed ID: 29576307
    [Abstract] [Full Text] [Related]

  • 5. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R, Reisinger K, Block SL, Izu A, Odrljin T, Dull P.
    J Pediatr; 2014 Jun 19; 164(6):1409-15.e4. PubMed ID: 24657122
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
    Macias Parra M, Gentile A, Vazquez Narvaez JA, Capdevila A, Minguez A, Carrascal M, Willemsen A, Bhusal C, Toneatto D.
    Vaccine; 2018 Nov 29; 36(50):7609-7617. PubMed ID: 30414782
    [Abstract] [Full Text] [Related]

  • 8. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R, Reisinger K, Block SL, Percell S, Odrljin T, Dull PM, Smolenov I.
    Pediatr Infect Dis J; 2014 Nov 29; 33(11):1169-76. PubMed ID: 24911896
    [Abstract] [Full Text] [Related]

  • 9. Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.
    Block SL, Christensen S, Verma B, Xie F, Keshavan P, Dull PM, Smolenov I.
    Vaccine; 2015 Apr 27; 33(18):2175-82. PubMed ID: 25744224
    [Abstract] [Full Text] [Related]

  • 10. MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.
    Tipton M, Daly W, Senders S, Block SL, Lattanzi M, Mzolo T, Barbi S, Pellegrini M, Keshavan P.
    Vaccine; 2019 Sep 30; 37(42):6171-6179. PubMed ID: 31495595
    [Abstract] [Full Text] [Related]

  • 11. Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults.
    Sáez-Llorens X, Beltran-Rodriguez J, Novoa Pizarro JM, Mensi I, Keshavan P, Toneatto D.
    Hum Vaccin Immunother; 2018 May 04; 14(5):1161-1174. PubMed ID: 29601256
    [Abstract] [Full Text] [Related]

  • 12. Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age.
    Vesikari T, Peyrani P, Webber C, Van Der Wielen M, Cheuvart B, De Schrevel N, Aris E, Cutler M, Li P, Perez JL.
    Hum Vaccin Immunother; 2020 Jun 02; 16(6):1280-1291. PubMed ID: 32598244
    [Abstract] [Full Text] [Related]

  • 13. Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.
    Baxter R, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M.
    Pediatr Infect Dis J; 2015 Nov 02; 34(11):1236-43. PubMed ID: 26237742
    [Abstract] [Full Text] [Related]

  • 14. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.
    Baxter R, Keshavan P, Welsch JA, Han L, Smolenov I.
    Hum Vaccin Immunother; 2016 May 03; 12(5):1300-10. PubMed ID: 26829877
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M.
    Vaccine; 2016 Oct 17; 34(44):5273-5278. PubMed ID: 27642132
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.
    Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM.
    Hum Vaccin Immunother; 2012 Dec 01; 8(12):1892-903. PubMed ID: 23032159
    [Abstract] [Full Text] [Related]

  • 17. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.
    Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM.
    Pediatr Infect Dis J; 2013 Apr 01; 32(4):e170-7. PubMed ID: 23114372
    [Abstract] [Full Text] [Related]

  • 18. Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2-10 Years of Age.
    Johnston W, Essink B, Kirstein J, Forleo-Neto E, Percell S, Han L, Keshavan P, Smolenov I.
    Pediatr Infect Dis J; 2016 Jan 01; 35(1):e19-27. PubMed ID: 26398741
    [Abstract] [Full Text] [Related]

  • 19. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
    Szenborn L, Block SL, Jackowska T, Konior R, D'Agostino D, Smolenov I, Toneatto D, Welsch JA.
    Pediatr Infect Dis J; 2018 May 01; 37(5):475-482. PubMed ID: 29329168
    [Abstract] [Full Text] [Related]

  • 20. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.
    Khatami A, Snape MD, Davis E, Layton H, John T, Yu LM, Dull PM, Gill CJ, Odrjlin T, Dobson S, Halperin SA, Langley JM, McNeil SA, Pollard AJ.
    Vaccine; 2012 Apr 16; 30(18):2831-8. PubMed ID: 22394992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.